Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients
A phase 1/2 trial of CD40 agonist mitazalimab in combination with chemotherapy in pancreatic ductal adenocarcinoma, run by Alligator Bioscience AB, active and no longer recruiting.
Overview
Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients is a phase 1/2 interventional study registered as NCT04888312 by Alligator Bioscience AB, with 94 participants enrolled, started 2021-09-17 and due to reach its primary completion in 2026-06-01. Interventions recorded: CD40 agonist mitazalimab in combination with chemotherapy.
Similar pages
not linked directly; found by shared links- TrialGlufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialA Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialFOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialAcoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialThe Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialRecombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialA Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.